TSPO and Miyoshi myopathy: The CIM provides an ideal model to track MM and determine the clinical efficacy of TSPO probes that target activated immune cells with the potential to lead to a reliable imaging tool to assess new therapeutic interventions [9,10,13,14,15,16].